TY - JOUR T1 - DECABROMODIPHENYL ETHER IN THE RAT: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 900 LP - 907 DO - 10.1124/dmd.31.7.900 VL - 31 IS - 7 AU - Anna Mörck AU - Heldur Hakk AU - Ulrika Örn AU - Eva Klasson Wehler Y1 - 2003/07/01 UR - http://dmd.aspetjournals.org/content/31/7/900.abstract N2 - Among the group of polybrominated diphenyl ethers used as flame-retardants, the fully brominated diphenyl ether, decabromodiphenyl ether (decaBDE), is the most commonly used. Despite the large usage of decaBDE, neither the metabolic pathways nor the absorption have been addressed, and there are very few studies on its toxicology. In this work, it is shown that after a single oral dose of 14C-labeled decaBDE to rats, at least 10% of the decaBDE dose is absorbed. The major excretion route in conventional rats is via feces that contained 90% of the decaBDE dose. The excretion in bile was close to 10% of the dose and represented mainly metabolites. It cannot be excluded that greater than 10% of the oral dose had been absorbed since 65% of the radioactivity excreted in feces was metabolites. The highest concentrations on a lipid weight basis were found in plasma and blood-rich tissues, and the adipose tissue had the lowest concentration of decaBDE. After derivatization of a phenolic fraction, gas chromatography-mass spectrometry (GC/MS) analyses indicated that metabolites with five to seven bromine atoms had formed, and they possessed a guaiacol structure (a hydroxy and a methoxy group) in one of the rings. In addition, traces of nonabrominated diphenyl ethers and monohydroxylated metabolites were found by GC/MS. Metabolites, characterized by their chemical properties, were interpreted to be covalently bound to macromolecules, either proteins or lipids. In addition, water solubility was suggested. The metabolic pathway was indicated to include a reactive intermediate. The American Society for Pharmacology and Experimental Therapeutics ER -